Radium-223 and Actinium-225 α-Emitter Radiopharmaceuticals in Treatment of Metastatic Castration-Resistant Prostate Cancer
In recent decades, multiple radiopharmaceutical conjugates have been tested and shown to be efficacious in treating metastasized castration-resistant prostate cancer (mCRPC). Several types of research have been published on the therapeutic use of α-emitter radiopharmaceuticals, and several authors s...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2022
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/78187 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | In recent decades, multiple radiopharmaceutical conjugates have been tested and shown to be efficacious in treating metastasized castration-resistant prostate cancer (mCRPC). Several types of research have been published on the therapeutic use of α-emitter radiopharmaceuticals, and several authors suggested their treatment superiority. One of the suggested methods is targeted alpha therapy. In this method, alpha radiation delivers energy to cancer cells and the tumor microenvironment while minimizing toxicity to surrounding tissues. In this chapter, the alpha emitter radiopharmaceutical applications in castration-resistant prostate cancer patients were investigated. Hence, we studied the 223Ra and 225Ac α-emitter radiopharmaceuticals application method and distribution of dose throughout human body organs. |
|---|---|
| ISBN: | 978-1-83969-659-6 |
| DOI: | 10.5772/intechopen.99756 |